|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn834604356 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
120614s2013 nyua ob 001 0 eng |
| 010 |
|
|
|a 2019720654
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d N$T
|d UKMGB
|d OCLCF
|d D6H
|d AGLDB
|d Z5A
|d VTS
|d AU@
|d STF
|d K6U
|d YDXCP
|d OCLCO
|d OCLCQ
|
| 016 |
7 |
|
|a 016156575
|2 Uk
|
| 020 |
|
|
|a 9781622574599
|q ebook
|
| 020 |
|
|
|a 1622574591
|
| 020 |
|
|
|z 9781621000716
|q (hbk.)
|
| 020 |
|
|
|z 1621000710
|q (hbk.)
|
| 029 |
1 |
|
|a NZ1
|b 14975484
|
| 029 |
1 |
|
|a DEBSZ
|b 472780085
|
| 029 |
1 |
|
|a DEBBG
|b BV043775532
|
| 035 |
|
|
|a (OCoLC)834604356
|
| 050 |
0 |
0 |
|a RM333.5
|
| 060 |
|
4 |
|a QV 77.9
|
| 072 |
|
7 |
|a MED
|x 093000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 105020
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7/882
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Antipsychotic drugs :
|b pharmacology, side effects and abuse prevention /
|c Thomas L. Schwartz, James Megna and Michael E. Topel, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2013]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Psychiatry- theory, applications, and treatments
|
| 500 |
|
|
|a "Nova Biomedical"
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination.
|
| 505 |
8 |
|
|a Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References.
|
| 505 |
8 |
|
|a Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole.
|
| 505 |
8 |
|
|a AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection.
|
| 505 |
8 |
|
|a Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Antipsychotic drugs.
|
| 650 |
|
0 |
|a Antipsychotic drugs
|x Side effects.
|
| 650 |
|
0 |
|a Medication abuse
|x Prevention.
|
| 650 |
1 |
2 |
|a Antipsychotic Agents
|
| 650 |
|
6 |
|a Neuroleptiques.
|
| 650 |
|
6 |
|a Neuroleptiques
|x Effets secondaires.
|
| 650 |
|
7 |
|a MEDICAL
|x Pain Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Psychiatry
|x Psychopharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Antipsychotic drugs.
|2 fast
|0 (OCoLC)fst00810669
|
| 650 |
|
7 |
|a Antipsychotic drugs
|x Side effects.
|2 fast
|0 (OCoLC)fst00810673
|
| 650 |
|
7 |
|a Medication abuse
|x Prevention.
|2 fast
|0 (OCoLC)fst01014858
|
| 700 |
1 |
|
|a Schwartz, Thomas L.,
|e editor.
|
| 700 |
1 |
|
|a Megna, James,
|e editor.
|
| 700 |
1 |
|
|a Topel, Michael E.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Antipsychotic drugs
|z 9781621000716
|w (DLC) 2012941953
|
| 830 |
|
0 |
|a Psychiatry- theory, applications, and treatments series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=548903
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10394893
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 548903
|
| 994 |
|
|
|a 92
|b IZTAP
|
